IPO
IVD Firm Anbio Biotechnology Files for IPO
The German IVD developer said that it plans to offer 1.6 million shares on the Nasdaq Global Market.
The firm has submitted its xR assay to the FDA and is prioritizing its entry into the minimal residual disease space.
Tempus AI Prices $410.7M Initial Public Offering
The oncology data company priced its initial public offering of 11.1 million shares at $37.00 per share.
Top Five Articles on 360Dx Last Week: Cue Health Shutters; Roche Updates Pipeline; More
Last week, readers were most interested in a story about Cue Health shutting its doors and laying off 218 employees following a turbulent year.
Tempus AI Files for Initial Public Offering
The company's flagship technology is the Tempus Platform, which has allowed it to amass a library of clinical and molecular oncology data.
May 13, 2024
Dec 21, 2022
Oct 27, 2022
Jul 14, 2022
South Korean Biotech Lunit Prices $28M IPO
Jul 11, 2022
Jan 6, 2022
Nov 10, 2021
Bluejay Diagnostics Prices $21.6M IPO
Sep 2, 2021
Cue Health Files for IPO for up to $100M
Jul 19, 2021
Sophia Genetics Increases IPO Target to $221M
Jul 14, 2021